Search - tctmd.com

Displaying 1 - 20 of 29

Sort: Relevancy | Date

News Conference News VIVA 2019

Hope for Bioresorbable Vascular Scaffolds in Peripheral Disease Below the Knee?

L.A. McKeown

November 06, 2019

Presentation TCT Abstracts Posters 2019

A 'Real-World' Multi-center Registry Evaluating Safety and Clinical Performance of Biodegradable Polymer Coated Ultra-Thin Everolimus-Eluting Stents: One-year Results From the PERFORM-EVER Registry

Presenter: Sridhar Kasturi

October 09, 2019

News Industry News

Two-year data shows trend towards lower target vessel failure with Indian stent Supraflex vs. Xience stent from Abbott

October 09, 2019

News Conference News TCT 2019

IVUS-XPL at 5 Years Shows Durability of Imaging Guidance in PCI

Caitlin E. Cox

October 08, 2019

News Conference News TCT 2019

PICCOLETO II: More Support for DCB Safety and Efficacy in Small Coronaries

L.A. McKeown

October 04, 2019

News Conference News TCT 2019

Ultrathin-Strut Orsiro Stent as Good as BioMatrix: BIODEGRADE

Michael O'Riordan

September 30, 2019

News Conference News TCT 2019

Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT

Caitlin E. Cox

September 26, 2019

News TCT 2019

TCT 2019 Day One: TWILIGHT and Onyx ONE Kick Things Off

Shelley Wood

September 26, 2019

News Conference News TCT 2019

Onyx ONE: Shorter DAPT Plus ZES Noninferior to Polymer-Free Stent in High-Bleeding-Risk Patients

L.A. McKeown

September 26, 2019

https://www.tctmd.com/news/ideal-lm-probes-short-dapt-and-bioabsorbable-polymer-stent-left-main-disease

News Conference News TCT 2019

IDEAL-LM Probes Short DAPT and a Bioabsorbable-Polymer Stent in Left Main Disease

Michael O'Riordan

September 26, 2019

Presentation TCT 2019

TCT 47: Five-Year Clinical Outcomes From Randomized Comparison of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Metallic Stents in Patients With Coronary Artery Disease From ABSORB China Trial

Presenter: Run-Lin Gao

September 25, 2019

Presentation TCT 2019

TCT 11: Everolimus-eluting Bioresorbable Scaffolds versus Drug-eluting Stents in Patients with Acute Myocardial Infarction – 2-Year Results of the Randomized ISAR-Absorb MI Trial

Presenter: Jens Wiebe

September 25, 2019

News Conference News ESC 2019

BIOSTEMI: Ultrathin-Strut Orsiro Superior to Xience for 1-Year TLF After Primary PCI

Caitlin E. Cox

September 10, 2019

News Daily News

More Acute Stent Thrombosis With Synergy Stent in Bern PCI Registry

Michael O'Riordan

August 14, 2019

News Industry News

SINOMED® Concludes Enrollment of the PIONEER III Randomized, Pivotal Study of the BuMA Supreme® Coronary Drug-Eluting Stent

July 23, 2019

Podcast TCTMD Talking Points

COMPARE ABSORB: A Randomized Trial of a Polymeric Everolimus-Eluting Bioresorbable Scaffold in High-Risk and Complex Lesions

July 17, 2019

News Industry News

SMT Announces CE* Mark for the Most Deliverable Stent Supraflex Cruz

July 11, 2019

News Conference News EuroPCR 2019

Firehawk Stent Still Holds Up Well to Xience at 2 Years: TARGET All Comers

Caitlin E. Cox

May 23, 2019

News Conference News EuroPCR 2019

BASKET-SMALL 2 Angiographic Substudy Supports Safety of DCBs in Small Coronary Vessels

L.A. McKeown

May 22, 2019

News Conference News EuroPCR 2019

Ultrathin Struts Show Strength in Small Vessels: BIO-RESORT at 3 Years

Caitlin E. Cox

May 21, 2019

Advertisement

Hope for Bioresorbable Vascular Scaffolds in Peripheral Disease Below the Knee?

A 'Real-World' Multi-center Registry Evaluating Safety and Clinical Performance of Biodegradable Polymer Coated Ultra-Thin Everolimus-Eluting Stents: One-year Results From the PERFORM-EVER Registry

Two-year data shows trend towards lower target vessel failure with Indian stent Supraflex vs. Xience stent from Abbott

IVUS-XPL at 5 Years Shows Durability of Imaging Guidance in PCI

PICCOLETO II: More Support for DCB Safety and Efficacy in Small Coronaries

Ultrathin-Strut Orsiro Stent as Good as BioMatrix: BIODEGRADE

Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT

TCT 2019 Day One: TWILIGHT and Onyx ONE Kick Things Off

Onyx ONE: Shorter DAPT Plus ZES Noninferior to Polymer-Free Stent in High-Bleeding-Risk Patients

IDEAL-LM Probes Short DAPT and a Bioabsorbable-Polymer Stent in Left Main Disease

TCT 47: Five-Year Clinical Outcomes From Randomized Comparison of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Metallic Stents in Patients With Coronary Artery Disease From ABSORB China Trial

TCT 11: Everolimus-eluting Bioresorbable Scaffolds versus Drug-eluting Stents in Patients with Acute Myocardial Infarction – 2-Year Results of the Randomized ISAR-Absorb MI Trial

BIOSTEMI: Ultrathin-Strut Orsiro Superior to Xience for 1-Year TLF After Primary PCI

More Acute Stent Thrombosis With Synergy Stent in Bern PCI Registry

SINOMED® Concludes Enrollment of the PIONEER III Randomized, Pivotal Study of the BuMA Supreme® Coronary Drug-Eluting Stent

COMPARE ABSORB: A Randomized Trial of a Polymeric Everolimus-Eluting Bioresorbable Scaffold in High-Risk and Complex Lesions

SMT Announces CE* Mark for the Most Deliverable Stent Supraflex Cruz

Firehawk Stent Still Holds Up Well to Xience at 2 Years: TARGET All Comers

BASKET-SMALL 2 Angiographic Substudy Supports Safety of DCBs in Small Coronary Vessels

Ultrathin Struts Show Strength in Small Vessels: BIO-RESORT at 3 Years

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content